BiotechTube
Monomer Bio

Monomer Bio

San Francisco, United States· Est.
monomerbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Monomer Bio operates at the intersection of synthetic biology and AI/ML, offering a laboratory automation platform specifically for cell culture. The company's core product is a software stack that connects to readily-available lab instruments, creating automated workcells for tasks like stem cell differentiation and cell line engineering, backed by AI-driven data interpretation. By digitizing and automating manual, repetitive processes, Monomer aims to reduce biological noise, eliminate key-person dependencies, and accelerate the pace of discovery in cell-based research. The company appears to be a privately-held, early-stage platform provider serving research institutions and biotech R&D teams.

Synthetic BiologyAI / Machine Learning

Technology Platform

A software platform that integrates standard lab instruments into automated workcells for cell culture, featuring AI-driven monitoring, data analysis, and protocol scheduling to enable autonomous biology research.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The growing reliance on complex, human-relevant in vitro models like organoids for drug discovery creates a pressing need for automated, reproducible cell culture systems.
The expansion of cell therapies and synthetic biology further drives demand for scalable and consistent cell engineering and differentiation workflows.
Monomer's software-centric, hardware-agnostic platform allows it to address this niche efficiently without the capital burden of building proprietary robots.

Risk Factors

Technical risk is high, as automating complex, multi-day biological processes is inherently challenging and requires extreme reliability.
The company faces competition from both large lab automation vendors and cloud lab providers, and must clearly differentiate its specialized cell culture focus.
Adoption risk exists in convincing scientists to change manual workflows, and the business model must scale beyond custom integration services.

Competitive Landscape

Monomer Bio competes in the lab automation space against large instrument manufacturers (e.g., Thermo Fisher, Agilent) offering robotic systems, and newer cloud lab providers (e.g., Strateos, Emerald Cloud Lab) offering remote access to fully automated labs. Its key differentiation is a specialized software platform focused exclusively on the automation, monitoring, and AI-driven optimization of cell culture workflows, leveraging customers' existing hardware.

More companies in Digital Health & Biotech SaaS →More companies in United States →